

# NHL: Mantle Cell Lymphoma Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_

Line of Therapy: \_\_1<sup>st</sup> Line \_\_2<sup>nd</sup> Line \_\_3<sup>rd</sup> Line \_\_3<sup>rd</sup> Line+ \_\_Maint ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

Biomarkers/Characteristics: (select all that apply)

CD20 status: \_\_Negative \_\_Positive HIV associated lymphoma: \_\_No \_\_Yes Transplant Candidate: \_\_No \_\_Yes

## First Line of Therapy (1<sup>st</sup> Line) | ASCT Candidates

**Alternating R-CHOP/R-DHAP:** cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, rituximab\* alternating with dexamethasone, cisplatin, cytarabine (Ara-C), and rituximab\*

**Nordic Regimen:** dose intensified rituximab\*, cyclophosphamide, vincristine (Vincasar), doxorubicin (Adriamycin), prednisone alternating with rituximab\* and high dose cytarabine (Ara-C)

## First Line of Therapy (1<sup>st</sup> Line) | Not an ASCT Candidate

**BR:** bendamustine (Bendeka, Treanda) and rituximab\*

## Second and Subsequent Lines of Therapy (2<sup>nd</sup> Line+)

**BR:** bendamustine (Bendeka, Treanda) and rituximab\*

Bortezomib (Velcade)

Ibrutinib (Imbruvica)

Lenalidomide (Revlimid)

\*Rituximab may be administered as Rituxan or Rituxan Hycela. When Rituxan Hycela is chosen, treatment with SC rituximab (Rituxan Hycela) should only be initiated after patients have received at least one full dose of IV rituximab (Rituxan)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.